Glioma clinical trials in Texas
26 studies for Glioma are looking for participants at sites in Texas.
Cities in Texas
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07326566A Phase I Clinical Study of YN003 in the Treatment of Glioma
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Nov 10, 2026 · NCT07929909Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
- M D Anderson Cancer Center, Houston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05804227ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Texas Children's Hospital, Houston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated Oct 23, 2026 · NCT06838676Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT06810544Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT05460507SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT05303519Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standard of Care Radiation
- The University of Texas M. D. Anderson Cancer Center, Houston
RecruitingPhase 1
36 Months · All sexes · Updated Oct 9, 2026 · NCT07076498Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Houston
- Research Site, San Antonio
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Oct 5, 2026 · NCT05417594A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568MRE Scan for the Assessment of Differences in Tissue Stiffness Between Radiation Necrosis and Recurrent Glioma in Patients With Previously Treated Gliomas
- M D Anderson Cancer Center, Houston
Recruiting
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04373720Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma
- M D Anderson Cancer Center, Houston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04771806Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 3 to 39 · All sexes · Updated Aug 24, 2026 · NCT05096481Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- M D Anderson Cancer Center, Houston
RecruitingObservational study
All ages · All sexes · Updated Aug 21, 2026 · NCT01772771Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)
- University Of Texas Southwestern Medical Center, Dallas
RecruitingPhase 1
Ages 1 to 25 · All sexes · Updated Aug 18, 2026 · NCT04485559Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
- Texas Children's Hospital, Houston
RecruitingPhase 1
12 Months – 25 Years · All sexes · Updated Aug 3, 2026 · NCT04099797A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 20, 2026 · NCT06326411A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Texas Children's Hospital, Houston
RecruitingEarly phase 1
Up to age 21 · All sexes · Updated Mar 18, 2026 · NCT04655404From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.